Showing results (311-320 of 355) with videos related to
Sort By:
Pageof 36
BMC Rheumatology|February 3, 2024
Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled studyLaura C Coates, Proton Rahman, Philip J Mease, et al.BMC Rheumatology|March 20, 2019
Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registryArthur Kavanaugh, Kim Papp, Alice B Gottlieb, et al.Rheumatology (Oxford, England)|September 14, 2022
Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysisPhilip J Mease, Iain B McInnes, Lai-Shan Tam, et al.Joint Bone Spine|January 27, 2023
Impact of key manifestations of psoriatic arthritis on patient quality of life, functional status, and work productivity: Findings from a real-world study in the United States and EuropeJessica A Walsh, Alexis Ogdie, Kaleb Michaud, et al.Clinical Rheumatology|July 21, 2021
Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 TO 2020A M Orbai, S M Reddy, N Dennis, et al.Journal of Dermatological Science|January 15, 2017
Application of whole exome sequencing in elucidating the phenotype and genotype spectrum of junctional epidermolysis bullosa: A preliminary experience of a tertiary care centre in IndiaVamsi K Yenamandra, Shamsudheen K Vellarikkal, Manoj Kumar, et al.RMD Open|February 24, 2023
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritisAlice B Gottlieb, Iain B McInnes, Proton Rahman, et al.Drugs - Real World Outcomes|July 31, 2024
Comparison of Real-World On-Label Treatment Persistence in Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Tumor Necrosis Factor InhibitorsJessica A Walsh, Iris Lin, Ruizhi Zhao, et al.Nanomedicine (London, England)|August 25, 2021
Graphene nanofiber composites for enhanced neuronal differentiation of human mesenchymal stem cellsSonali Rawat, Krishan Gopal Jain, Deepika Gupta, et al.Clinical Rheumatology|June 6, 2024
Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 studyChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.Pageof 36